At Exelixis, our vision is to be a commercial world-class biotechnology company.
Exelixis is a biopharmaceutical company committed to developing and commercializing small molecule therapies for the treatment of cancer.
In advancing COMETRIQ® (cabozantinib), our first commercial product, from discovery to market, we have put in place an effective and integrated infrastructure that encompasses the entire biopharmaceutical development continuum. Areas of expertise include early discovery and preclinical development, clinical development, translational medicine, regulatory affairs, and sales and marketing, among other functions. In addition, we have leveraged our earlier stage capabilities to establish multiple partnerships and collaborations with leading pharmaceutical and biopharmaceutical companies. These partnerships are designed to advance the development of a variety of targeted therapies.
We are committed to excellence in all aspects of our work and are dedicated to improving the care and outcome of cancer patients.